Hayward, California-based Arcus Biosciences, Inc. (NYSE:RCUS), a company in the pharmaceutical preparations industry with a market capitalization of $1.2 billion, announced today a change to its Board ...

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

When the next patient asks me about a game-changing HIV prevention tool, I hope I can say, “It’s already here and available to everyone who needs it.” ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...